Drug Trial Radar · NCT05578976
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
900
Planned (sponsor's estimate)
Start
Feb 8, 2023
Primary completion
Jun 2027
Study completion Dec 2029
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- First posted
- Oct 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of this study is to assess the change in disease activity of epcoritamab when combined with intravenous and oral rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) or R-CHOP in adult participants globally with diffuse large b-cell lymphoma (DLBCL). Change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of DLBCL. Study doctors put the participants in groups called treatment arms. Participants will receive epcoritamab combined with R-CHOP, followed by epcoritamab or R-CHOP followed by rituximab will be explored. Approximately 900 adult participants with with newly diagnosed DLBCL will be enrolled in the study in approximately 315 sites in globally. In the Arm 1, participants will receive subcutaneous epcoritamab combined with intravenous and oral R-CHOP followed by subcutaneous epcoritamab in 21-day cycles. In the Arm 2, participants will receive intravenous and oral R-CHOP followed by intravenous rituximab in 21-day cycles. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Conditions
- Diffuse Large B-Cell Lymphoma
Interventions
EpcoritamabDrug
Subcutaneous Injection (SC)
CyclophosphamideDrug
Intravenous (IV) Injection
RituximabDrug
IV Infusion
VincristineDrug
IV Infusion
DoxorubicinDrug
IV Infusion
PrednisoneDrug
Oral; Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Progression-Free Survival (PFS) with an International Prognostic Index (IPI) of 3-5Time frame: Up to Approximately 46 Months
Locations
331 sites in 31 countries. Site status is shown where the registry gives one.
Duplicate_University of Arizona Cancer Center - North Campus /ID# 227463
Tucson, Arizona
Yuma Regional Medical Center Cancer Center /ID# 261527
Yuma, Arizona
University of Arkansas for Medical Sciences /ID# 225703
Little Rock, Arkansas
CBCC Global Research, Inc. /ID# 262037
Bakersfield, California
Alta Bates Summit Medical Center for Research /ID# 229427
Berkeley, California
Orange Coast Memorial Medical Center /ID# 229632
Fountain Valley, California
Providence - St. Jude Medical Center /ID# 262042
Fullerton, California
Saddleback Memorial Medical Center /ID# 229631
Laguna Hills, California
Long Beach Memorial Medical Ct /ID# 228996
Long Beach, California
Cancer and Blood Speciality Clinic - Los Alamitos /ID# 262032
Los Alamitos, California
University of Southern California /ID# 225443
Los Angeles, California
University of California, Los Angeles /ID# 226887
Los Angeles, California
Kaiser Permanente, Waterpark III Institute for Health Research /ID# 228618
Aurora, Colorado
Duplicate_Cancer Specialists of North Florida /ID# 226826
Jacksonville, Florida
Ocala Oncology Florida Cancer Affiliates - Main /ID# 262785
Ocala, Florida
Orlando Health Cancer Institute /ID# 232626
Orlando, Florida
Straub Medical Center /ID# 229464
Honolulu, Hawaii
University of Illinois at Chicago /ID# 226889
Chicago, Illinois
Southern IL Univ School of Med /ID# 228999
Springfield, Illinois
Springfield Clinic Main Campus /ID# 262584
Springfield, Illinois
Carle Cancer Institute /ID# 228338
Urbana, Illinois
Parkview Comprehensive Cancer Center /ID# 227026
Fort Wayne, Indiana
Goshen Center for Cancer Care /ID# 225534
Goshen, Indiana
University of Iowa Health Care /ID# 261945
Des Moines, Iowa
Cancer Center of Kansas /ID# 261983
Wichita, Kansas
Norton Cancer Institute - St. Matthews /ID# 225420
Louisville, Kentucky
University of Maryland, Baltimore /ID# 225421
Baltimore, Maryland
Johns Hopkins Hospital /ID# 225369
Baltimore, Maryland
American Oncology Partners of Maryland /ID# 226859
Bethesda, Maryland
UMass Memorial Medical Center /ID# 226939
Worcester, Massachusetts
University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 225462
Ann Arbor, Michigan
Trinity Health St. Joseph Mercy Ann Arbor /ID# 228206
Ypsilanti, Michigan
Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 226680
Saint Louis Park, Minnesota
University of Mississippi Medical Center /ID# 228045
Jackson, Mississippi
Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana /ID# 259014
Billings, Montana
NHO Revive Research Institute, LLC /ID# 261113
Lincoln, Nebraska
MDACC Cooper /ID# 260320
Camden, New Jersey
Titan Health Partners LLC, d/b/a Astera Cancer Care /ID# 226654
East Brunswick, New Jersey
Morristown Medical Center /ID# 239457
Morristown, New Jersey
University of New Mexico /ID# 227332
Albuquerque, New Mexico
Showing 40 of 331 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.